Announcement PDF ABN 16 165 160 841 ASX RELEASE 12 August 2024 AMPLIA RECEIVES R&D TAX REBATE TOTALLING $ 3.2 MILLION Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to advise that it has received a Research and Development (R&D) Tax Incentive refund of $3,177,718 for the 2023/2024 financial year. The refund relates to expenditure incurred in research and development associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886. These R&D activities primarily related to the Company’s ongoing Phase 1b/2a clinical trial of narmafotinib in advanced pancreatic cancer patients. Following receipt of the funds, the Company will fully repay the loan of $1,467,000 received from Director Dr Robert Peach along with accrued interest 1. The net funds will contribute to the further progression of the Company’s Phase 1b/2a clinical trial of narmafotinib and other R&D activities. The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities. This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics. - End Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. 1 Quarterly Activities And Cash Flow Reports 30 January 2024 Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com